New Endometriosis Tests: What to Know

Endometriosis affects about 10 percent of women and girls of reproductive age, yet diagnosis often takes years. New non-invasive tests claim to shorten that path. Some are already sold online or promoted through social media; others remain in clinical validation. The central question is whether these tests can reliably detect a disease that has historically required surgery to confirm.

This article explains what the new tests measure, what the evidence shows, and what patients should ask before using one.

Why Endometriosis Is Hard to Diagnose

Endometriosis occurs when tissue similar to the uterine lining grows outside the uterus. It can cause pelvic pain, painful periods, pain during sex, infertility, fatigue, and bowel or bladder symptoms. Symptoms vary widely, and some people have extensive disease with few symptoms.

The diagnosis gap is real. Studies report an average delay of 7 to 10 years from symptom onset to diagnosis. During that time, patients may see multiple clinicians and receive misdiagnoses such as irritable bowel syndrome, pelvic inflammatory disease, or primary dysmenorrhea.

Symptom Overlap Delays Recognition

Many endometriosis symptoms overlap with other common conditions. Bloating, diarrhea, constipation, and abdominal pain mimic irritable bowel syndrome. Pelvic pain can be attributed to bladder conditions, muscle dysfunction, or psychological stress. Heavy or painful periods may be dismissed as normal.

This overlap means symptom-based diagnosis alone is unreliable. Clinicians need objective markers, but those markers have been difficult to identify.

Imaging Has Limits

Transvaginal ultrasound and pelvic MRI can detect some forms of endometriosis, especially ovarian endometriomas and deeply infiltrating disease. However, superficial peritoneal endometriosis, one of the most common forms, is often missed on imaging.

The accuracy of imaging depends heavily on operator skill and specialist protocols. A standard pelvic ultrasound may be normal in a patient with significant disease.

Laparoscopy Is the Current Gold Standard

Surgical visualization with biopsy remains the standard for definitive diagnosis. During laparoscopy, a surgeon can inspect pelvic organs and take tissue samples. Confirmation requires histology showing endometrial-like glands and stroma outside the uterus.

Laparoscopy is invasive, requires anesthesia, carries risks, and is not accessible to everyone. It also may not be offered early enough. This creates the demand for non-invasive tests.

What the New Tests Claim to Do

New diagnostic tests fall into several categories. They aim to detect molecular signals, imaging patterns, or combinations of biomarkers that correlate with endometriosis.

Blood-Based Biomarker Panels

Some tests measure proteins, cytokines, growth factors, or microRNAs in blood. The premise is that endometriosis alters systemic inflammation, immune function, and gene expression, leaving a measurable signature.

A challenge is that many biomarker panels are developed in small case-control studies. They may perform well in research settings but decline when tested in broader populations with other pelvic conditions.

Salivary microRNA Tests

Saliva tests have attracted attention because they are non-invasive and easy to collect. Some commercial tests analyze microRNAs in saliva that may be linked to endometriosis.

The appeal is clear: a spit test could be done at home or in a clinic without a blood draw or imaging. But the evidence base is contested. Validation studies differ in design, and independent replication is limited.

Menstrual Effluent and Endometrial Biopsy Tests

Menstrual blood contains cells and molecules shed from the endometrium. Researchers have tested menstrual effluent for stem cell markers, nerve fibers, and gene expression patterns associated with endometriosis.

Endometrial biopsy tests look for altered expression of genes such as BCL6 or markers of progesterone resistance. These approaches may help identify a subset of patients, but they do not always distinguish endometriosis from other inflammatory or hormonal conditions.

Advanced Imaging and AI-Assisted Detection

Some specialists now use structured ultrasound protocols, bowel preparation, and experienced sonographers to improve detection of deep endometriosis. Artificial intelligence models are being trained to flag suspicious lesions on ultrasound or MRI.

AI tools may standardize image interpretation, but they require large, diverse training datasets and external validation. An algorithm that works in one hospital system may not perform equally in another.

Multi-Omic and Machine-Learning Panels

Newer research combines genomics, proteomics, metabolomics, and clinical data. Machine-learning models then classify patients as likely or unlikely to have endometriosis.

These approaches are promising but raise concerns about overfitting, lack of reproducibility, and commercial release before independent confirmation.

What the Evidence Shows

A test can be useful only if its sensitivity and specificity are high enough across the intended population. Sensitivity is the ability to detect true positives. Specificity is the ability to avoid false positives.

Claims Often Outpace Validation

Many non-invasive tests report sensitivity above 90 percent and specificity above 90 percent. Those numbers may come from small studies or enriched populations with a high prevalence of endometriosis.

When applied to a broader population, test performance can drop. A test with 90 percent sensitivity and 90 percent specificity still produces many false results when disease prevalence is low or when patients have other pelvic conditions.

Study Design Weaknesses

Common limitations in endometriosis biomarker research include:

• Small sample sizes
• Case-control designs that do not reflect real-world patients
• Lack of surgical confirmation in controls
• Exclusion of people with fibroids, adenomyosis, or pelvic infection
• Manufacturer involvement in study design or analysis
• Selective reporting of favorable results

Without large prospective studies that include surgical confirmation, the true accuracy is unknown.

Regulatory Status Varies

Some tests are marketed as laboratory-developed tests and may not require full regulatory approval in all countries. Others have CE marking in Europe but are not cleared by the U.S. Food and Drug Administration for diagnosis.

Patients may assume that a commercially available test is proven and regulated. That assumption is not always correct. A CE mark does not necessarily mean the test has been independently validated as a standalone diagnostic for endometriosis.

What Experts and Medical Societies Say

Major gynecology organizations emphasize that laparoscopy with histologic confirmation remains the gold standard. They urge caution about non-invasive tests that claim to replace surgery.

Professional Society Positions

The American College of Obstetricians and Gynecologists and the European Society of Human Reproduction and Embryology support clinical diagnosis and empirical treatment in some cases. However, they do not currently endorse any single blood, saliva, or menstrual test as a definitive diagnostic tool for all patients.

Some societies acknowledge that non-invasive tests may have a role in triage or research, but they should not be used alone to rule in or rule out endometriosis.

Risk of False Reassurance

A negative test result may lead some patients to stop seeking care for ongoing pain. That is dangerous if the test misses early or superficial disease.

Risk of Overtreatment

A false positive result may lead to unnecessary hormonal suppression, repeated imaging, or even surgery. In some cases, a positive commercial test may push a patient toward laparoscopy that finds no endometriosis.

The Need for Independent Replication

Experts want independent validation in diverse populations, including adolescents, perimenopausal patients, and people with coexisting conditions. A biomarker that tracks inflammation may be elevated in many disorders, not only endometriosis.

How to Evaluate a New Test

Patients and clinicians can use a simple framework when assessing a non-invasive test.

Check the Clinical Claim

Ask what the test is intended to do: screen, triage, aid diagnosis, or confirm disease. A test that says it can assist clinical assessment differs from one that claims to provide a definitive diagnosis.

Look at the Evidence

Search for peer-reviewed validation studies. Check whether the study included surgical confirmation, an independent control group, and researchers without financial ties to the manufacturer.

Understand the Numbers

Ask for sensitivity, specificity, positive predictive value, and negative predictive value in the population most like you. A test that performs well in a fertility clinic may not perform the same in an adolescent pain clinic.

Consider the Consequences

Ask what happens after a positive or negative result. Would a positive result lead to surgery, hormonal treatment, or further imaging? Would a negative result delay needed care?

What Patients Should Ask a Clinician

Before paying for a new test, consider these questions.

• Is this test validated in patients with my age, symptoms, and history?
• Has it been independently reproduced outside the developers research group?
• How will the result change my treatment plan?
• If the test is negative, will my symptoms still be investigated?
• Is laparoscopy or specialist imaging still recommended?
• Does insurance cover this test, or will I pay out of pocket?

A careful clinician will not rely on an unvalidated test as the final word.

The Future of Endometriosis Diagnosis

The field is moving toward earlier recognition and better triage, but progress is incremental.

Combination Approaches

The most likely future is a combination of symptom assessment, imaging, and biomarker panels. No single test may be sufficient. A risk score using multiple data sources may help general clinicians decide when to refer to a specialist.

Ongoing Prospective Studies

Large multicenter studies are evaluating candidate biomarkers with surgical confirmation. These studies include control groups with other pelvic pathologies, which is necessary for real-world accuracy.

Early Detection and Fertility Preservation

If reliable early detection becomes possible, patients may start treatment sooner and preserve fertility. That is the strongest argument for continued research. But early detection requires tests that work in adolescents and young adults, not just in patients already scheduled for surgery.

The Bottom Line

New tests for endometriosis are promising but not yet definitive. Some may help as part of a broader diagnostic workup. None should replace clinical judgment, specialist imaging, or surgical confirmation without stronger independent evidence.

Patients deserve tests that are accurate, accessible, and validated in the people who need them most. Until then, a skeptical, evidence-based approach is the right one.

FAQ

1. Can a blood test diagnose endometriosis?

A blood test cannot currently provide a definitive diagnosis of endometriosis. Some blood-based biomarker panels show potential in research, but they lack large, independent validation with surgical confirmation. They may be used as part of a broader assessment, not as standalone proof.

2. Are saliva tests for endometriosis reliable?

Saliva microRNA tests are marketed as non-invasive options, but their reliability remains debated. Independent studies have reported lower accuracy than the original developer-led studies. A saliva test may provide additional information, but it should not be the only basis for ruling endometriosis in or out.

3. Do I still need laparoscopy if a new test is positive?

A positive non-invasive test does not eliminate the need for specialist evaluation. Laparoscopy with biopsy remains the standard for definitive diagnosis. A positive test may support the decision to pursue surgery, but it should be interpreted with imaging and symptoms.

4. Will a negative test result rule out endometriosis?

No. A negative result from an unvalidated test cannot rule out endometriosis. Superficial peritoneal endometriosis and early disease may not produce a detectable molecular signal. If symptoms persist, further evaluation is needed.

5. Are these new tests covered by insurance?

Coverage depends on the test, the country, and whether the test has regulatory approval and established clinical validity. Many new biomarker tests are paid out of pocket because insurers consider them experimental or not medically necessary.

6. What is the most reliable way to diagnose endometriosis today?

The most reliable method remains laparoscopy with histologic confirmation. In some cases, specialist imaging and clinical symptoms can support a presumptive diagnosis and guide treatment. Non-invasive tests are not yet a substitute for surgical diagnosis.